Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Lifordi Immunotherapeutics

Request full access

Lifordi is among the first companies to leverage the success of antibody-drug conjugates (ADC) to develop treatments for autoimmune and inflammatory disorders

Boston, United StatesFounded 2023Biotech & Life Sciences

About Lifordi Immunotherapeutics

Lifordi Immunotherapeutics is a pioneering biotechnology company focused on developing targeted antibody drug conjugates (ADCs) to treat autoimmune and inflammatory disorders. Leveraging the success of ADCs in oncology, Lifordi aims to revolutionize the treatment landscape for these conditions by targeting myeloid and lymphoid cells using a highly internalized cell surface membrane protein. The company operates in the biopharmaceutical market, serving patients with autoimmune and inflammatory diseases. Lifordi's business model involves the discovery, development, and commercialization of novel therapeutics, supported by funding from prominent venture capital firms such as ARCH Venture Partners, 5AM Ventures, and Atlas Venture. Revenue is generated through partnerships, licensing agreements, and eventual product sales. The company's leadership team boasts extensive experience in drug development, immunology, and inflammatory diseases, positioning Lifordi as a leader in this specialized field.

Source: Dealroom company data

At a glance

Status
Operational
Employees
22
Open positions
2
Dealroom signal
36.9/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
LATE VCOther financing Nov 2025 $112M $448M Atlas Venture · ARCH Venture Partners · 5AM Ventures · Sanofi Ventures ↗
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Lifordi Immunotherapeutics website traffic

Latest recorded traffic for Lifordi Immunotherapeutics is 300 monthly website visits, down 96.2% over the last three months. Lifordi Immunotherapeutics's team declined 4.3% over the past year.

Latest monthly visits300 3-month web change-96.2% 1-year team growth-4.3%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Lifordi Immunotherapeutics in the Boston ecosystem

Live from Dealroom

The Lifordi Immunotherapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

4 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later4 investors entered at this stage

Team profiled 2 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States94.1%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Lifordi Immunotherapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Lifordi Immunotherapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.